Steve Cartt

Steve Cartt joined Neurelis as a board member in January 2020. He previously served as President and CEO of Asterias Biotherapeutics and was a board member from 2016 until its acquisition in 2019 by BioTime, Inc., where he previously was a board member from 2014 to 2016.

Mr. Cartt served as Chief Operating Officer of Questcor Pharmaceuticals, Inc., from 2012 to 2014 until the company was acquired by Mallinckrodt plc. Mr. Cartt served as Chief Operating Officer of the Autoimmune and Rare Diseases business unit of Mallinckrodt plc on an interim basis in 2014 following the merger with Questcor. He originally joined Questcor as Executive Vice President, Corporate Development, in 2005. He was later appointed Chief Business Officer and then Chief Operating Officer. Mr. Cartt was a private consultant from 2002 to 2005. Between 2000 and 2002, he was the Senior Director of Strategic Marketing for Elan Pharmaceuticals. Prior to that, Mr. Cartt held a variety of R&D and commercial positions at ALZA Corporation from 1985 to 2000.

Mr. Cartt holds a BS degree from the University of California at Davis in biochemistry, and an MBA from Santa Clara University.